...
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >Dosing issues in Parkinson's disease - patient preferences and their influence on compliance
【24h】

Dosing issues in Parkinson's disease - patient preferences and their influence on compliance

机译:帕金森氏病的剂量问题-患者喜好及其对依从性的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Since James Parkinson first described the eponymous-ly named neurodegenerative disease, as well as its successful treatment with opium [1], other drugs have been described to be efficacious in ameliorating the motor and non-motor manifestations of Parkinson's disease (PD). Indeed, optimal management of PD may require careful titration of multiple drugs, including levodopa, dopamine agonists (DA), catechol-O-methyltransferase inhibitors, monoamine oxidase inhibitors, amantadine,anticholinergics among others, to maintain optimal motor function and quality of life [2]. Levodopa therapy, with and without selegiline, is thought to prolong survival in PD sufferers [3,4], but its short half-life means that the dopamine receptors are stimulated in a pulsatile manner.
机译:自从詹姆斯·帕金森(James Parkinson)首次描述了同名的神经退行性疾病及其成功的鸦片治疗[1]以来,已有其他药物被描述为可有效改善帕金森氏病(PD)的运动和非运动表现。实际上,PD的最佳管理可能需要仔细滴定多种药物,包括左旋多巴,多巴胺激动剂(DA),儿茶酚-O-甲基转移酶抑制剂,单胺氧化酶抑制剂,金刚烷胺,抗胆碱能药等,以维持最佳的运动功能和生活质量[ 2]。左旋多巴疗法(含或不含司来吉兰)被认为可延长PD患者的生存期[3,4],但其半衰期短意味着以脉冲方式刺激多巴胺受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号